App-Quantinova.ai

AGI-134, a fully synthetic -Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles.

Sascha A. Kristian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer-Results of the UK ColoRectal Endoscopic Stenting Trial (CREST).

James Hill - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Left-sided malignant colonic obstruction

stannous fluoride

Salvage surgery with abdominoperineal excision of the rectum (APER) following loco-regional failure after chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) and the impact on long-term outcomes: Results of ACT II.

Robert Glynne-Jones - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anal squamous cell carcinoma

mitomycin

Oncological benefit of parenchyma-preserving hepatectomy for colorectal liver metastasis.

Isamu Hosokawa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

N/A

Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.

Marc Peeters - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs).

Jenny F. Seligmann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Irinotecan

Prognostic utility of the presence of extramural vascular invasion in stage II and III colorectal cancer: data from the FACS randomised controlled trial.

Sian Alexandra Pugh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Immune profile and survival outcomes in stage 2 colon cancer.

Peter Gibbs - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.

Jochen Prehn - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Adrucil injection

NETTER-1 Phase III: Progression-Free Survival, Radiographic Response and Preliminary Overall Survival Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotate

Jonathan R. Strosberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Octreotide

Evofosfamide (TH-302) in Combination with Gemcitabine in Previously Untreated Patients with Metastatic or Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma: Primary Analysis of the Randomized, Double-Blind Phase III MAESTRO Study

Eric Van Cutsem - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Evofosfamide

PET-PANC: Multi-Centre Prospective Diagnostic Accuracy and Clinical Value Trial of FDG PET/CT in the Diagnosis and Management of Suspected Pancreatic Cancer

Paula Ghaneh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Hyun Cheol Chung - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Avelumab

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

Yelena Yuriy Janjigian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Ipilimumab

Phase III Randomized Study of Second Line ADI-Peg 20 (A) Plus Best Supportive Care Versus Placebo (P) Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Pegargiminase

TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC): Background.

Tim Meyer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Doxorubicin

A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

Davide Melisi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

LY2157299

Prediction of malignant progression of Barretts oesophagus: A complete systematic review and meta-analysis.

Kiran Altaf - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).

Darren R Hodgson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Methadone hydrochloride

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).

Crystal Shereen Denlinger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Trastuzumab

Filters

45280 Abstracts